The company developing products to modulate the human microbiome to prevent, manage, and treat human disease has last week announced a £1.5m placing at 75p which will help to drive development and commercialisation in its existing programmes but also to pursue opportunities in new application areas. As part of the placing directors of the company subscribed for £110k worth of shares.
14 Dec 2015
Taking the human microbiome into new territory
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Taking the human microbiome into new territory
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
14 Dec 2015 -
Author:
Derren Nathan -
Pages:
8
The company developing products to modulate the human microbiome to prevent, manage, and treat human disease has last week announced a £1.5m placing at 75p which will help to drive development and commercialisation in its existing programmes but also to pursue opportunities in new application areas. As part of the placing directors of the company subscribed for £110k worth of shares.